跳至內容

烏美溴銨

維基百科,自由的百科全書
烏美溴銨
臨床資料
商品名英語Drug nomenclatureIncruse Ellipta
其他名稱GSK573719A、蕪地溴銨
核准狀況
給藥途徑吸入(DPI英語Dry powder inhaler
ATC碼
法律規範狀態
法律規範
藥物動力學數據
血漿蛋白結合率~89%[2]
藥物代謝CYP2D6
生物半衰期11 hours
排泄途徑糞便(58%)和尿液(22%)
識別資訊
  • Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
CAS號869113-09-7
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.166.375 編輯維基數據鏈接
化學資訊
化學式C29H34BrNO2
摩爾質量508.50 g·mol−1
3D模型(JSmol英語JSmol
  • OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2.[Br-]
  • InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
  • Key:PEJHHXHHNGORMP-UHFFFAOYSA-M

烏美溴銨INN:umeclidinium bromide;商品名:Incruse Ellipta),或譯蕪地溴銨,是一種長效毒蕈鹼拮抗劑,被批准用於慢性阻塞性肺病(COPD)的維持治療。[2]它還被批准與維蘭特羅烏美溴銨/維蘭特羅)聯合用於該適應症[3][4]以及作為糠酸氟替卡松/烏美溴銨/維蘭特羅的三重療法組合。[5]

它被列入世界衛生組織的基本藥物清單[6]2020年,它是美國第245位最常用處方藥物,處方數量超過100萬張。[7][8]

參考資料

  1. ^ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. (原始內容存檔於2023-04-10). 
  2. ^ 2.0 2.1 Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. [22 February 2016]. (原始內容 (PDF)存檔於10 July 2018). 
  3. ^ Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Therapeutic Advances in Respiratory Disease. December 2013, 7 (6): 311–9. PMID 24004659. S2CID 5744282. doi:10.1177/1753465813499789. 
  4. ^ FDA Approves Umeclidinium and Vilanterol Combo for COPD. Medscape. December 18, 2013 [2024-03-07]. (原始內容存檔於2017-09-24). 
  5. ^ TRELEGY ELLIPTA Package Insert (PDF). GlaxoSmithKline. September 2017 [11 July 2020]. (原始內容存檔 (PDF)於2020-07-12). 
  6. ^ World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533可免費查閱. WHO/MHP/HPS/EML/2021.02. 
  7. ^ The Top 300 of 2020. ClinCalc. [7 October 2022]. (原始內容存檔於2021-02-12). 
  8. ^ Umeclidinium - Drug Usage Statistics. ClinCalc. [7 October 2022]. (原始內容存檔於2023-09-24). 

外部連結

  • Umeclidinium. Drug Information Portal. U.S. National Library of Medicine. [2024-03-07]. (原始內容存檔於2022-12-01). 
  • Umeclidinium bromide. Drug Information Portal. U.S. National Library of Medicine. [2024-03-07]. (原始內容存檔於2022-06-02).